TrialBreast cancer research : BCR2025

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Elena López-Miranda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.